JAMA Network
About The Study: Compared with prior decades, the number of new dermatologic drug approvals by the Food and Drug Administration (FDA) increased between 2012 and 2022. Nearly half of these drugs were considered first in class or first in indication, and several were deemed clinically useful or to have high added therapeutic benefit by health technology assessment organizations in Germany, Canada, or France.
Authors: Ravi Gupta, M.D., M.S.H.P., of the Johns Hopkins University School of Medicine in Baltimore, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamadermatol.2023.5036)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
